Is AVRTF or ABBV a better dividend investment in 2026?

AVRTF currently yields 5000.00% with a 5% 5-year dividend growth rate. ABBV yields 3.12% with 8.9% growth. The better choice depends on your goal: AVRTF offers higher current income.

What is the dividend yield difference between AVRTF and ABBV?

AVRTF has a forward dividend yield of 5000.00% ($2.00/share annually). ABBV yields 3.12% ($6.65/share annually). The yield gap is 4996.88 percentage points.

Home › Compare › AVRTF vs ABBV

AVRTF vs ABBV: Dividend Comparison 2026

AVRTF yields 5000.00% · ABBV yields 3.12%● Live data

vsPost on X →

After 10 years · $10,000 invested · DRIP enabled

🏆 AVRTF wins by $62217131802825.24M in total portfolio value

INVESTMENT

TIME HORIZON10 years

AVRTF

● Live price

5000.00%

Share price

$0.04

Annual div

$2.00

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$62217131802825.35M

Annual income

$59,861,980,287,378,210,000.00

Full AVRTF calculator →

ABBV

AbbVie Inc.

● Live price

3.12%

Share price

$213.22

Annual div

$6.65

5Y div CAGR

40.6%

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$104.7K

Annual income

$25,725.73

Full ABBV calculator →

Portfolio growth — AVRTF vs ABBV

📍 AVRTF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis Period	AVRTF	ABBV
2008–2009 GFC	— No data	— No data
2020 Q1–Q2 COVID	— No data	— No data
2022 Q4 Rate Hike	— No data	— No data

Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.

📅

Dividend Calendar Overlap

Combined, AVRTF + ABBV cover 0 of 12 months — good coverage

Jan

—

Feb

—

Mar

—

Apr

—

May

—

Jun

—

Jul

—

Aug

—

Sep

—

Oct

—

Nov

—

Dec

—

AVRTF pays

ABBV pays

Both pay

Neither

💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

AVRTF

Annual income on $10K today (after 15% tax)

$425,000.00/yr

After 10yr DRIP, annual income (after tax)

$50,882,683,244,271,480,000.00/yr

ABBV

Annual income on $10K today (after 15% tax)

$265.10/yr

After 10yr DRIP, annual income (after tax)

$21,866.87/yr

At 15% tax rate, AVRTF beats the other by $50,882,683,244,271,450,000.00/year in after-tax income after 10 years on $10,000

⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of AVRTF + ABBV for your $10,000?

AVRTF: 50%ABBV: 50%

100% ABBV50/50100% AVRTF

Portfolio after 10yr

$31108565901412.73M

Annual income

$29,930,990,143,689,118,000.00/yr

Blended yield

96.21%

📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

AVRTF

No analyst data

Altman Z

-7891.1

Piotroski

2/9

ABBV

Analyst Ratings

Buy

Hold

Sell

Consensus: Buy

Price Target

$256.15

+20.1% upside vs current

Range: $223.00 — $299.00

Altman Z

2.0

Piotroski

8/9

Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.

🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

AVRTF buys

ABBV buys

No recent congressional trades found for AVRTF or ABBV in the last 90 days.

STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →

MetricAVRTFABBV

Forward yield	5000.00% ✓	3.12%
Annual dividend / share	$2.00	$6.65 ✓
Payout ratio	50%	50%
1-year div growth	0%	0%
5-year div CAGR	0%	40.6% ✓
Portfolio after 10y	$62217131802825.35M ✓	$104.7K
Annual income after 10y	$59,861,980,287,378,210,000.00 ✓	$25,725.73
Total dividends collected	$62057786341622.61M ✓	$63.0K
Payment frequency	quarterly	quarterly
Sector	Stock	Healthcare

Year-by-year: AVRTF vs ABBV ($10,000, DRIP)

Year	AVRTF Portfolio	AVRTF Income/yr	ABBV Portfolio	ABBV Income/yr	Gap
1← crossover	$510,700	$500,000.00	$11,559	$438.51	+$499.1K → AVRTF
2	$24,410,935	$23,864,485.98	$13,494	$640.86	+$24.40M → AVRTF
3	$1,092,192,501	$1,066,072,800.30	$15,951	$945.97	+$1092.18M → AVRTF
4	$45,746,366,951	$44,577,720,975.17	$19,152	$1,413.89	+$45746.35M → AVRTF
5	$1,793,932,828,410	$1,744,984,215,772.56	$23,443	$2,146.38	+$1793932.80M → AVRTF
6	$65,871,973,805,320	$63,952,465,678,921.49	$29,391	$3,321.96	+$65871973.78M → AVRTF
7	$2,265,146,887,602,700	$2,194,663,875,631,007.20	$37,948	$5,265.87	+$2265146887.56M → AVRTF
8	$72,954,689,148,998,180	$70,530,981,979,263,280.00	$50,795	$8,596.74	+$72954689148.95M → AVRTF
9	$2,201,076,182,660,884,700	$2,123,014,665,271,456,500.00	$71,034	$14,549.41	+$2201076182660.81M → AVRTF
10	$62,217,131,802,825,350,000	$59,861,980,287,378,210,000.00	$104,715	$25,725.73	+$62217131802825.24M → AVRTF

AVRTF vs ABBV: Complete Analysis 2026

AVRTF — Stock

Avarone Metals Inc., an exploration stage company, engages in the acquisition, exploration, and development of precious metals and energy-based resource properties in Canada. The company was formerly known as Remstar Resources Ltd. and changed its name to Avarone Metals Inc. in January 2014. Avarone Metals Inc. was incorporated in 1993 and is headquartered in Vancouver, Canada.

Full AVRTF Calculator →

ABBV — Healthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →

📬

Get this AVRTF vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

AVRTF vs SCHD AVRTF vs JEPI AVRTF vs O AVRTF vs KO AVRTF vs MAIN AVRTF vs JNJ AVRTF vs MRK AVRTF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.